Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MGAM-001
- Development stage
- Unknown
- Modality
- Cell Therapies
01
Overview
MGAM-001 is an investigational cell-based therapy being evaluated for white matter repair in infants with periventricular leukomalacia, a form of neonatal white matter brain injury associated with motor and cognitive impairments.[7] It is administered as a biological cell therapy product with the aim of promoting remyelination and neural repair in damaged periventricular white matter, potentially improving long-term neurodevelopmental outcomes.[7] Specifics on the exact cell type, manufacturing platform, and detailed mechanism of action have not been publicly disclosed, but the trial is structured as an early-phase safety and feasibility study in this high-risk pediatric population.[7]
Beyond the preview
Go deeper on MGAM-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MGAM-001.